Unichem Laboratories Ltd
NSE: UNICHEMLAB BSE: 506690
₹346.20
(-1.18%)
Mon, 09 Mar 2026, 00:16 pm
Market Cap24.44B
PE Ratio8.28
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1962
- The Company was incorporated on 22nd August, at Bombay.
- The Company manufactures pharmaceutical products and chemicals on behalf of Uni-U.C.B.(India) Pvt.Ltd., associates of the reputed UCB of Brussels, Belgium.
- Government approved the scheme to manufacture dextran and iron dextran cycoside in collaboration with Roshkilde Medical Company of Denmark.
- Government also approved the Collaboration Scheme with Shofu Dental Mfg.Co.Ltd., Japan, for the manufacture of dental products.
- The Company was formed to take over as a going concern the proprietary business carried on since 1944, at Bombay, by Shri A V Mody as manufacturing chemist and dealer in pharmaceuticals and medicines, under the name and style of 'Unichem Laboratories'.
1983
- The Upjohn division was established, the name was changed to UNISEARCH division with effect from 1st October, 1987.
1992
- Unichem Exports Limited ceased to be a subsidiary of the company from 17th November.
1993
- The Company introduced a new antibiotic in the market, and incurred substantial cost on the new launch.
1994
- The Company made an Issue of Equity Shares to the shareholders, promoters and employees as a result of which the Equity share Capital has increased to Rs.199.12 lacs.
1995
- The Pharma Division extended its products range by launching two new molecules and one additional formulation in the market.
- 5,59,900 No. of Equity Warrants were allotted to the Promoters/Promoter Group.
1998
- The Company has launched three new products in three different therapeutic areas i.e. Cardiovascular, Anti Inflammatory and Anti oxidant under the brand names CORVADIL-A, PRONIM and PRO-RIDAGE.
- The company has a technical collaboration with Shofu Dental Manufacturing Co, Japan and Roshkilde Medical Co, Denmark.
- The Company has launched three new products in three different therapeutic areas viz., Satin a cholesterol reducer in the area of cardiovascular therapeutic segment; Domadol in the post operative pain management segment and Zonep in the psychiatry segment.
- The company recently commissioned a Rs 20-crore manufacturing facility at Bardez in Goa, specially designed to meet stringent standards in export markets.
1999
- The Company's new Division mainly catering to Women's Healthcare called FOREVA was launched on 1st April.
- The Company has launched eight new products, Losar, Serta, Biclar, Zisper, M-cam, Flospar, Lanpro, Anticox 3.
- Unichem Laboratories, a leading pharmaceutical company, has launched M-Cam', a non-steroidal anti-inflammatory drug (NSAID) for the treatment or arthritis.
- The company has recently commissioned its multi-purpose facility at Roha in Maharashtra to manufacture a range of bulk drugs scheduled to go off patent in advanced markets by 2000.
- The company has tied up with Aptech and NIIT to reach a majority of the nearly 3,000 cardiologists and over 20,000 physician MDs in the country.
2000
- Unichem Laboratories has entered into a strategic alliance with the Korean Green Cross Corporation to market Urokinase.
- The Company has introduced Celib for management of arthritis.
- Unichem Laboratories has launched Zulu, the first muscle relaxant containing nimesulide and tizanidine.
- The Foreva, the Women's healthcare division of the company has acquired the marketing and distribution rights for Partobulin (Anti-D Immunoglobulin) in India from Baxter Healthcare.
- The Company will launch its own version of Pfizer's impotence pill Viagra under the brand name Erix.
2001
- Foreva, the women's healthcare division of Unichem Laboratories, has entered into a technical tie-up with the US-based Protein Technologies International Inc, a DuPont division, for developing a soya protein supplement for women called Nutreva.
2002
- Enters into Joint Venture with the former Directors of the Bioglan group in Ireland.
- Bharat Bio signs marketing alliance with the company to market hepatitis-B, recombinant.
- Ind-Swift ties up with the company for Co-marketing pact to co-market finished dosages of its anti-depressant drug citalopram
2003
- Registered a net profit increase by around 10.6% in the I quarter at Rs.9.4crs for the same period last year.
- Enters into an agreement for the sale of its Animal Healthcare Division to M/s Tetragon Chemie Ltd.
- Appoints Mr Prafful D Sheth as the Director of the company.
- Unichem Laboratories Ltd, a Mumbai based Rs 475-crore pharmaceutical company, has received ISO 9001 & 14001 certificates
2006
- Unichem Laboratories enters into agreement with PLIVA inc, USA
2009
- Unichem Laboratories Ltd has appointed Mr. Harcharan Singh as Chief Executive - Pharma with effect from March 24, 2009.
2010
- Unichem Laboratories Ltd has received approval from US Food & Drug Administration (U.S. FDA) for Hydrochlorothiazide Capsules in the strengths of 12.5 mg
- Unichem Laboratories Ltd strengthened 6.38% to close at Rs 381.15 as the company has received EU GMP certificate from IRISH Medicines Board for the 12 API's manufactured at Company's Roha plant.
- Company has splits its Face value of Shares from Rs 5 to Rs 2
2011
- Unichem Laboratories Ltd has received approval from US Food & Drug Administration (FDA) for Divalproex Sodium Delayed Release Tablets USP 125mg, 250mg and 500mg (Valproic -Acid Activity).
2012
- Mr. Bhagwat S. Dhingra has been appointed as Chief Executive - Domestic Pharma
- Unichem Laboratories receives ANDA tentative approval from USFDA for IRBESARTAN TABLETS
- Unichem gets tentative nod from USFDA for dementia tablets.
2013
- Unichem Laboratories receives ANDA approval from USFDA for Amlodipine Besylate Tablets
- Unichem Laboratories has recommended Dividend of Rs. 4.50 (225%) per equity share of Rs. 2/- each.
2014
- Unichem Laboratories receives ANDA approval from USFDA for Metronidazole USP Tablets
- Unichem Laboratories has recommended Final Dividend of Rs. 4/- (200%) per equity share of Rs. 2/- each.
2015
- Unichem bags ANDA approval for Montelukast Sodium tablets
- Acquired API manufacturing unit at Kolhapur
- Commissioned expanded capacities at Goa plant
2017
- Divested domestic formulation business to Torrent Pharma
2019
- Strategic investment in Hyderabad based Optimus Drugs Pvt Ltd. & Optrix Laboratories Pvt Ltd.
- New plant site acquired in Goa
- Product facility expansions in Ghaziabad and Pithampur
2020
- Unichem Laboratories gets USFDA nod to market generic version of tolterodine tartrate tablets.
2021
- Unichem Laboratories receives USFDA approval for Aripiraprazole tablets.
- Unichem Laboratories receives USFDA approval for Zonisamide Capsules.
- Unichem Laboratories gets USFDA nod for plaque psoriasis treatment drug.
- New Oral Solid Dosage manufacturing facility commissioned at Goa Plant II.
2022
- Unichem Laboratories receives ANDA approval for Extended Phenytoin Sodium Capsules.
- Unichem Labs gets US FDA nod for Schizophrenia drug.
2023
- Ipca Laboratories Limited acquires 52.67% of the paid-up share capital of Unichem.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800